摘要
评价血清前列腺特异性抗原 (PSA)在前列腺癌与前列腺增生症 (BPH)鉴别诊断中的意义。采用化学发光免疫法 (CLIA)检测 10名健康志愿者、2 3例前列腺癌患者、6 1例BPH患者、11例BPH伴急性尿潴留患者血清PSA。对其中 16例前列腺癌患者进行 1- 6个月随访检测。结果 :① 10名正常志愿者血清PSA均小于 4μg/L ;前列腺癌组血清PSA明显升高 ,BPH组及BPH伴急性尿潴留组血清PSA亦高于正常 ,后三组间在统计学上均有显著差异性 (P <0 .0 1)。②CLIA法检测血清PSA的鉴别诊断阈值以 2 0 μg/L为低限。③ 16例前列腺癌患者术后 1个月内血清PSA均下降。其中 14例病情稳定者血清PSA下降至正常 ,2例病情恶化者术后 3个月血清PSA迅速回升。血清PSA对鉴别诊断前列腺良、恶性疾病具有重要价值 。
The areicle was to evaluate the clinical value of serum prostate specific antigen(PSA) in differentiation between benign prostatic hyperplasia (BPH) and prostate cancer(PCA). By means of chemiluminescence immunoassay(CLIA), a quantitative assay of serum PSA has been done on 10 controls and 95 patients (23 pationts with prostate cancer, 61 patients with BPH and 11 pationts with acute urinary retention), while 16 patients with PCA were followed-up from 1 to 6 months, Results: ①serum PSA of 10 controls were below 4 μg/L, while the PSA of the group with PCA increased significantly, the PSA of the groups with BPH and BPH with acute urinary retention increased too. There were significant differences statistically among the latter three groups ( P <0.01); ②the differential level of serum PSA assayed by CLIA was 18.14 μg/L as the lowest limit; ③serum PSA of 16 cases with PCA decreased within 1 month after operation, 14 cases whose disease kept stable decreased till normal, and 2 aggravated cases increased within 3 months after operation. Serum PSA has important value in differentiating PCA from benign prostate disease and also aids to observe the treatment response and prognosis.
出处
《标记免疫分析与临床》
CAS
2001年第3期137-139,共3页
Labeled Immunoassays and Clinical Medicine
